Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported Operating Income Loss of $584.90 million for the year ending 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +2.6% in Operating Income Loss from 2024 to 2025.
- This data is from WEST PHARMACEUTICAL SERVICES INC's annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: $28.90 million | Q2 2010: $30.50 million | Q3 2010: $25.30 million | Q1 2011: $28.80 million | Q2 2011: $27.80 million | Q3 2011: $26.10 million | Q1 2012: $41.70 million | Q2 2012: $35.60 million | Q3 2012: $26.30 million | Q1 2013: $43.30 million | Q2 2013: $42.50 million | Q3 2013: $39.70 million | Q1 2014: $39.30 million | Q2 2014: $54.10 million | Q3 2014: $44.00 million | Q1 2015: $47.80 million | Q2 2015: $39.10 million | Q3 2015: -$3.50 million | Q1 2016: $30.00 million | Q2 2016: $61.20 million | Q3 2016: $51.30 million | Q1 2017: $60.50 million | Q2 2017: $42.00 million | Q3 2017: $62.90 million | Q1 2018: $53.40 million | Q2 2018: $60.30 million | Q3 2018: $60.80 million | Q1 2019: $70.70 million | Q2 2019: $80.50 million | Q3 2019: $67.30 million | Q1 2020: $88.00 million | Q2 2020: $103.60 million | Q3 2020: $99.20 million | Q1 2021: $175.60 million | Q2 2021: $211.30 million | Q3 2021: $181.40 million | Q1 2022: $189.70 million | Q2 2022: $228.40 million | Q3 2022: $186.20 million | Q1 2023: $155.30 million | Q2 2023: $182.50 million | Q3 2023: $177.30 million | Q1 2024: $122.80 million | Q2 2024: $126.20 million | Q3 2024: $161.30 million | Q1 2025: $107.00 million | Q2 2025: $153.70 million | Q3 2025: $167.60 million.
- Over the full 18 years of available data (2008 to 2025), WEST PHARMACEUTICAL SERVICES INC's Operating Income Loss has grown by 371.3%.
- Historical annual values: Fiscal year 2025: $584.90 million | Fiscal year 2024: $569.90 million | Fiscal year 2023: $676.00 million | Fiscal year 2022: $734.00 million | Fiscal year 2021: $752.30 million | Fiscal year 2020: $406.90 million | Fiscal year 2019: $296.60 million | Fiscal year 2018: $240.30 million | Fiscal year 2017: $225.80 million | Fiscal year 2016: $195.20 million | Fiscal year 2015: $128.60 million | Fiscal year 2014: $182.00 million | Fiscal year 2013: $162.40 million | Fiscal year 2012: $135.10 million | Fiscal year 2011: $109.60 million | Fiscal year 2010: $90.70 million | Fiscal year 2009: $97.50 million | Fiscal year 2008: $124.10 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: